(VIANEWS) – Shares of BeiGene (NASDAQ: BGNE) rose by a staggering 20.88% in 10 sessions from $215 at 2023-04-04, to $259.89 at 14:37 EST on Wednesday, after two consecutive sessions in a row of gains. NASDAQ is rising 0.16% to $12,172.50, following the last session’s downward trend.
BeiGene’s last close was $266.78, 4.93% under its 52-week high of $280.62.
About BeiGene
BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Enlivex Therapeutics Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
Earnings Per Share
As for profitability, BeiGene has a trailing twelve months EPS of $-19.58.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.11%.
Volatility
BeiGene’s last week, last month’s, and last quarter’s current intraday variation average was 1.16%, 0.87%, and 1.99%.
BeiGene’s highest amplitude of average volatility was 1.49% (last week), 2.13% (last month), and 1.99% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BeiGene’s stock is considered to be oversold (<=20).
More news about BeiGene (BGNE).
